Ultragenyx Pharmaceutical Q2 EPS $(2.25) Misses $(2.11) Estimate, Sales $108.31M Beat $105.20M Estimate
Portfolio Pulse from totan@benzinga.com
Ultragenyx Pharmaceutical reported Q2 losses of $(2.25) per share, missing the analyst consensus estimate of $(2.11) by 6.64%. However, the company's quarterly sales of $108.31 million beat the analyst consensus estimate of $105.20 million by 2.96%. This represents a 21.23% increase over sales from the same period last year.
August 04, 2023 | 2:18 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ultragenyx Pharmaceutical's Q2 earnings per share missed estimates, but sales exceeded expectations, indicating mixed financial performance.
Ultragenyx Pharmaceutical's Q2 earnings per share missed the consensus estimate, which could negatively impact investor sentiment. However, the company's sales exceeded expectations, which could offset some of the negative impact. The net effect on the stock price is uncertain in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100